PARK2/Parkin Ubiquitin Ligase Pathway in Parkinson's Disease

PARK2/Parkin Ubiquitin Ligase Pathway in Parkinson's Disease

Overview

PARK2 (parkin) is an E3 ubiquitin ligase that plays a central role in mitochondrial quality control through the process of mitophagy — the selective autophagy of damaged mitochondria. Pathogenic mutations in PARK2 cause autosomal recessive juvenile-onset Parkinson's disease (AR-JP), typically with onset before age 40. The loss of parkin function leads to accumulation of dysfunctional mitochondria, increased oxidative stress, and progressive dopaminergic neuron death in the substantia nigra[@parkin2024].

Parkin Protein Structure and Function

Structural Architecture

Parkin is a 465-amino acid protein containing multiple functional domains:

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal Ub-like (Ubl) | Residues 1-76 | Binding to autophagy receptors (p62, HDAC6) |
| RING0 (R0) | 77-140 | Autoinhibitory; blocks RING1 activity |
| RING1 | 141-227 | E2-binding, ubiquitin transfer |
| In-Between-RING (IBR) | 228-327 | Structural; contributes to active conformation |
| RING2 | 328-465 | Catalytic; contains the HECT-like active site |

Catalytic Mechanism

PARK2/Parkin Ubiquitin Ligase Pathway in Parkinson's Disease

Overview

PARK2 (parkin) is an E3 ubiquitin ligase that plays a central role in mitochondrial quality control through the process of mitophagy — the selective autophagy of damaged mitochondria. Pathogenic mutations in PARK2 cause autosomal recessive juvenile-onset Parkinson's disease (AR-JP), typically with onset before age 40. The loss of parkin function leads to accumulation of dysfunctional mitochondria, increased oxidative stress, and progressive dopaminergic neuron death in the substantia nigra[@parkin2024].

Parkin Protein Structure and Function

Structural Architecture

Parkin is a 465-amino acid protein containing multiple functional domains:

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal Ub-like (Ubl) | Residues 1-76 | Binding to autophagy receptors (p62, HDAC6) |
| RING0 (R0) | 77-140 | Autoinhibitory; blocks RING1 activity |
| RING1 | 141-227 | E2-binding, ubiquitin transfer |
| In-Between-RING (IBR) | 228-327 | Structural; contributes to active conformation |
| RING2 | 328-465 | Catalytic; contains the HECT-like active site |

Catalytic Mechanism

Parkin is a RING-type E3 ligase (RING-between-RING architecture):

Regulation of Parkin Activity

Autoinhibition and Activation

Parkin is kept inactive in the cytosol through an intramolecular interaction where RING0 blocks the RING1-E2 binding interface. Activation requires:

PINK1-Parkin Pathway

Pathogenic Mutations

Mutation Distribution

PARK2 mutations are the most common cause of autosomal recessive PD, accounting for ~50% of familial PD with onset <30 years and ~10-15% of early-onset PD overall. Over 200 pathogenic mutations have been identified throughout the gene.

Common Mutation Types

| Mutation Type | Frequency | Effect |
|---------------|-----------|--------|
| Exon deletions (exons 3, 4, 5) | ~30% | Loss-of-function |
| Point mutations | ~40% | Missense, nonsense |
| Copy number variants | ~20% | Deletions/duplications |
| Splice site mutations | ~10% | Exon skipping |

Genotype-Phenotype Correlations

• Homozygous deletions (N-terminal): earlier onset, more severe
• Compound heterozygotes: variable phenotype
• Single heterozygous: typically not sufficient for PD (recessive inheritance)
• Missense variants: variable penetrance; some may be risk factors rather than causal

Parkin in Mitophagy

Step-by-Step Mitophagy Cascade

Step 1: Mitochondrial Damage Sensing

• Loss of mitochondrial membrane potential (Δψm) prevents PINK1 import
• PINK1 accumulates on the outer mitochondrial membrane (OMM)
• PINK1 autophosphorylates and gains full kinase activity

• PINK1 phosphorylates both Ser65 on the Ubl domain of parkin AND Ser65 on ubiquitin molecules on the OMM
• pS65-ubiquitin is a unique "eat-me" signal

• Phospho-ubiquitin binds to the RING0 domain of parkin
• PINK1 phosphorylates parkin's Ubl domain at Ser65
• This relieves autoinhibition; parkin adopts an open conformation
• Parkin can now interact with E2~Ub conjugates

• Parkin ubiquitinates multiple OMM proteins:
• Miro1/2 (mitochondrial Rho GTPases) — marks mitochondria for sequestration
• VDAC1/2 (voltage-dependent anion channels) — pore components
• Mfn1/2 (mitofusins) — fusion proteins on OMM
• TOM20, TOM70 (translocase components)
• Pink1 itself (amplification loop)

• p62/SQSTM1 binds to polyubiquitin chains via its UBA domain
• p62 also binds LC3 via its LIR domain
• This links ubiquitinated mitochondria to the forming autophagosome

• Autophagosome membrane extends around the tagged mitochondria
• Fusion with lysosome delivers contents for degradation
• Mitochondrial components are recycled

Parkin Beyond Mitophagy

Regulation of Other Cellular Processes

1. Synaptic Vesicle Trafficking

Parkin ubiquitinates proteins involved in synaptic vesicle dynamics:

• Synaptojanin 1: involved in synaptic vesicle endocytosis
• Synaptic vesicle proteins: direct tagging for quality control
• Rim: active zone protein involved in neurotransmitter release

2. Proteasome-Mediated Degradation

Parkin targets proteins for degradation via the 26S proteasome:

• Pael receptor (GPR37): accumulates in parkin-null mice, causes ER stress
• AIMP1/p43: translational control
• HSP70: co-chaperone with misfolded protein clients

3. Immune Regulation

Parkin modulates inflammatory responses:

• Negatively regulates NF-κB signaling
• Regulates TNF-α-induced cell death
• Parkin-deficient cells show exaggerated inflammatory responses

Parkin in Dopaminergic Neurons

Dopaminergic neurons are particularly vulnerable to parkin loss because:

Clinical Features of PARK2-PD

Phenotype

| Feature | Details |
|---------|---------|
| Age at onset | Typically 20-40 years (range 3-66) |
| Disease progression | Slower than idiopathic PD |
| Motor symptoms | Tremor less common, dystonia more common |
| Non-motor | Cognitive impairment less frequent early |
| Response to L-DOPA | Good initial response |
| Psychiatric | Depression, anxiety common |
| Dystonia | Limb dystonia at onset in many |

Imaging

• DAT PET/SPECT: Shows dopaminergic deficit, similar to idiopathic PD
• MRI: Generally unremarkable
• PET for inflammation: May show reduced microglial activation

Therapeutic Strategies

Gene Replacement

Restoring parkin expression using AAV vectors:

| Program | Approach | Stage |
|---------|----------|-------|
| AAV-PARK2 | AAV2/9-delivered PARK2 | Preclinical |
| AAV10-PARK2 | High-efficiency CNS delivery | Preclinical |

Small Molecule Activation

Direct pharmacological activation of parkin is challenging because the gain of function requires structural changes. However:

• Cell-permeable parkin mimetics: research stage
• PINK1 activators: indirect activation via PINK1 substrate enhancement
• Ubiquitin chain stabilizers: maintain ubiquitination for longer

Mitochondrial Protection

| Approach | Mechanism | Stage |
|---------|-----------|-------|
| Mitochondrial antioxidants | Reduce oxidative damage | Clinical |
| MitoQ | Targeted CoQ10 delivery | Phase 2 |
| Bendavia/SS-31 | Peptide targeting mitochondrial cardiolipin | Phase 2 |

Mitophagy Enhancement

| Approach | Mechanism | Stage |
|---------|-----------|-------|
| Urolithin A | Induces mitophagy | Phase 2 (sarcopenia) |
| NAD+ precursors | Enhances mitophagy via PGC-1α | Phase 2 |
| AMPK activators | Stimulate autophagy/mitophagy | Preclinical |

Biomarkers

Functional Biomarkers

| Biomarker | Assessment | Parkin-Pathway Status |
|-----------|-----------|----------------------|
| Imaging of mitochondrial mass | PET, MRI spectroscopy | Elevated in parkin deficiency |
| Oxidized DJ-1 | Plasma | Elevated in PD |
| Mitochondrial DNA copy number | Blood, iPSC | Altered in mutation carriers |
| PolyUb chains on mitochondria | Immunohistochemistry | Reduced in parkin-PD |

Research Frontiers

References

See Also

• [Amyotrophic lateral sclerosis, motor neuron disease](/diseases/amyotrophic-lateral-sclerosis)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [Spinal muscular atrophy](/diseases/sma)
• [Spinobulbar muscular atrophy](/diseases/kennedy-disease)
• [SOD1, ALS-linked protein](/proteins/sod1-protein)
• [TDP-43, ALS/FTD pathology](/proteins/tdp43-protein)
• [FUS, ALS-linked protein](/proteins/fus-protein)
• [SMN protein, SMA target](/proteins/smn-protein)
• [Neuroinflammation](/mechanisms/neuroinflammation-cross-disease)
• [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Protein degradation](/mechanisms/ubiquitin-proteasome-system)
• [Motor neurons](/cell-types/motor-neurons)
• [Bulbar motor neurons](/cell-types/bulbar-neurons)
• [Mitophagy mechanisms](/mechanisms/mitophagy-mechanisms)
• [E3 ubiquitin ligases](/mechanisms/ubiquitin-ligase-pathways)